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Abstract 
Background: Regarding the role of vitamin D3 as a steroid hormone in regulating the metabolism of minerals and 
bone homeostasis, its antitumor role has been confirmed in epidemiologic and empirical studies. Accordingly, this 
investigation conducted on acute lymphoblastic leukemia (ALL) patients to understand whether vitamin D3 has role 
in increasing the risk of getting ALL or not. Materials and Methods: In this study, 40 patients with acute 
lymphoblastic leukemia were included after confirmation of cytological tests in Hamedan, Qazvin and Tehran. 
Moreover, 40 healthy persons without any hematologic diseases in both themselves and their immediate relatives 
were selected. The level of vitamin D3 in blood serum of patients and control group was measured with 
Chemiluminscence method. Results: Ninety percent of the subjects in the experimental group and 75% of the 
control group suffered from severe vitamin D3 deficiency. 10% of the experimental group and 20% of the control 
group had a mild to moderate vitamin D3 deficiency and range from 10 - 19 ng / ml. Among ALL patients, none 
of them had the desired level (20- 50 ng / ml) of vitamin D3, while two persons in the control group had a 
desirable level of vitamin D3 with a range of 20- 50 ng / ml. It is found that there is a significant difference 
between mean of vitamin D3 level in acute lymphoblastic leukemia patients and healthy control group (p <0.05). 
Conclusion: It seems that there is a correlation between the incidence of ALL and serum vitamin D3 level. 
However, additional studies are needed to understand more about the mechanisms of this. 
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    Leukemia is the most prevalent cancer in 
childhood with 32% frequency among all childhood 
cancers. Annual incidence of leukemia was 3.7 and 
4.9 per 100 000 population in Tabriz and Ardebil (1) 
. According to our knowledge there is no accurate 
incidence of ALL in Iran. The most common type of 
leukemia among children is acute lymphoblastic 
leukemia (ALL) which comprise 80% of childhood 
(2-5years) leukemia. However, ALL can affect adult 
as well but with far less frequency (about 20% of 
ALL). There are different subtypes of ALL according 
to cellular morphology, immunophenotype, gene 
expression and genetic abnormality which some of 
them are with poor and some with good prognosis (2-
4).  
     Ionizing radiation, magnetic exposure, 
poisonous chemical substances, viral infection, and 
alcohol and tobacco consumption in parents has been 
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shown that can increase the risk of ALL in children. 
Moreover, it has been found that children with Down 
syndrome are 15 times more susceptible to affecting 
by ALL in comparison with healthy children. 
Splenomegaly, fever, bone pain, neutropenia and low 
hemoglobin level are the most common reported 
manifestations for affected patients (5-7). 
     Vitamin D3 is a steroid hormone, which 
has a very important role in calcium metabolism and 
phosphor and calcium homeostasis. Additionally, it 
has major role in cell differentiation, apoptosis and 
angiogenesis (8). Considering the important role of 
vitamin D3 in biological mechanisms in human body, 
specifically in bone homeostasis as steroid hormone, 
its anti-tumor activity has been confirmed in 
epidemiological and empirical studies (9). As an 
instance, individuals with undesirable level of 
vitamin D3 are more prone to cancer and have higher 
mortality due to breast cancer, colorectal and prostate 
cancer in comparison with person with normal level 
of vitamin D3 (10). Antitumor activity of vitamin D3 
is through prevention of proliferation and invasion of 
tumor cells. Vitamin D3 inhibits BCL2 (B-cell 
lymphoma 2) expression by BOX induction and 
induction of apoptosis in chronic lymphoid leukemia 
(11). Vitamin D3 level below 20ng/ml consider as 
vitamin D3 deficiency and the level of 20 to 29 ng/ml 
and 30 ng/ml consider as insufficient and normal 
level of vitamin D3 respectively (12). 
     With respect to clinical importance of ALL 
and leading role of vitamin D3 in cancers, current 
investigation aim to evaluate association between 
ALL and vitamin D3 level. 
Methods 
     Study population. In this case-control 
investigation, 40 ALL patients as experimental group 
and 40 healthy individuals as control group with the 
age mean of 9.3 years were included. ALL in patients 
had been confirmed by clinical findings, cellular 
morphology, and flow cytometry before in well-
equipped clinical centers in Iran (Ali Asghar hospital 
of Tehran and Besat educational and therapeutic 
center of Hamedan province). Moreover, patients had 
not any other cancers beside ALL and any immediate 
relatives affected by cancer. Study subjects in control 
group were without any blood diseases in not only 
themselves but also in their immediate relatives. 
Additionally, those who were under chemotherapy, 
radiotherapy or immunotherapy were excluded from 
this study. Written Patients consent form was given to 
all study subjects and was filled by them before 
beginning any procedures. Furthermore, some 
demographic characteristics including age and place of 
residence was questioned from study subjects.   
Laboratory Measurements. Initially, 5 ml vein 
blood sample without anticoagulant were collected 
from all the study subjects. Immediately, samples were 
sent to laboratory for serum separation and further 
procedures and were kept in -20° C refrigerator until 
subsequent use.To evaluate vitamin D3 level, 
chemiluminscence assay performed on each sample 
using DiaSorin LIAISON 25 OH vitamin D total assay 
kit according to the kit protocol and by LIAISON 
immunoanalyzer.  
     Statistical Analysis. Data were collected and 
analyzed by IBM SPSS 22. P value calculated by t-test 
and considered as significant when it was less than 
0.05.     
Results 
This study was carried out on 40 healthy and 40 
ALL patients. The age mean among patients and 
control subjects was similar (Table 1). The mean age 
of patients group was 9.30 ± 2.24 year as compared to 
that of control group 9.37 ± 1.95 year (mean ± SD). 
There was no significant differences in age between 
control group and patients group. 
 
Table 1.The age status of the study subjects. Forty ALL 
patients and 40 healthy control were included 
 Age 
mean SD Minimum Maximum 
Patients 
group 
9.3 2.24 6 15 
Control 
group 
9.375 1.95 6 15 
SD, standard deviation 
Regard to place of residence, percentage of 
those who reside in villa was higher in both control 
and experimental group (Table 2). In patients group 
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52.5% and 47.5% housing in villa and apartment 
respectively. Moreover, higher number 60% in 
control group was housing in villa and 40% residence 
in apartment.  
 
Table 2.  Place of residence distribution among study 
subjects. (40 patients with ALL versus to 40 healthy control). 
 Place of residence by percentage  








Vitamin D3 level was measured using 
chemiluminescence analyzer and it was found that 90 
percent (36 out of 40) of experimental group and 75 
percent (30 out of 40) suffer from sever vitamin D3 
deficiency. Moreover, some individuals in 
experimental and control group suffer from mild to 
moderate vitamin D3 deficiency ( 10-19 ng/dl ) , 
Furthermore, it was observed  that 10 % in control 
(n=4) and 20% (n=8)  in patients group, respectively 
(Figure 1). In the control group, two person (5%) 
found to have desirable level of vitamin D3 (20-50 
ng/ml. But   none of the patients group had desirable 
level (20-50 ng/ml vitamin) of vitamin D3 (Figure 1).  
 
 
Figure 1: Comparison of vitamin level between control (     ) 
and patient groups (   ). Numbers of controls and patients 
are shown on top of the columns. 
 
 
The mean of vitamin D3 level in control group 
was significantly higher than patents group due to 
existence of some persons with normal level of 
vitamin D3 (Table 3).  The mean vitamin D3 level was 
4.15 ng/dl ± 3.59 (mean ± SD) as compared to control 
group. The mean of vitamin D3 level in control group 
was 7.35 ± 7.95 ng/dl (mean ± SD; min 3, max 30). 
The Statistical analysis was performed on mean of 
vitamin D3 level in the control and the experimental 
group and it is found that there was a significant 
difference between mean of vitamin D3 level in them 
(p <0.05). Accordingly. There was an inverse 
relationship between vitamin D3 level and acute 
lymphoblastic leukemia risk. 
 
Table 3. Vitamin D3 level in control and experimental group. 
Forty ALL patients and 40 healthy control were included in 
Vitamin D3 level determination 
 Mean SD Maximum Minimum 
Patients 
group 
4.15 3.59 3 17 
Control 
group 
7.35 7.95 3 36 
SD, standard deviation 
 
Discussion 
This case control investigation conducted on 
ALL patients and healthy persons to find out if 
vitamin D3 has role in increasing the risk of getting 
ALL. ALL is the most frequent kind of leukemia in 
children. Indeed, it includes 80% of childhood (2-5 
years) leukemia though can affect adult as well (13). It 
is indicated that those with undesirable level of 
vitamin D3 are susceptible to cancer and have higher 
mortality due to breast cancer, colorectal and prostate 
cancer in comparison with person with normal level of 
vitamin D3 (10). Recent studies have shown that 
vitamin D3 inhibits BCL2 expression by BOX 
induction and induction of apoptosis in chronic 
lymphoid leukemia (11). Furthermore, active form of 
vitamin D3 can make change in apoptosis and 
regulator of cell cycle like P21 and P27 that lead to 
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prevention of cells proliferation (14). 
The current study, shown that there is a 
significant difference between mean of vitamin D3 
serum concentrations level of control and ALL 
patients (p <0.05). In a study carried out on 2562 
volunteers in Washington, Garland et al. indicated 
that those with serum vitamin D3 concentration of 
more than 20 ng/ml run less risk of colon cancer 
(15). Another investigation conducted on 105 
patients affected by blood cancer including ALL, 
dysplasia and acute and chronic lymphoid disorders 
in 2011. They found that there is a significant 
association between response to treatment and the 
level of vitamin D3 of below 25 ng/ml (16). 
      Shnafeit et al. in 2010 in a study on 390 
patients affected by chronic lymphoblastic leukemia 
found that 30.5% (119 patients) have low level of 
vitamin D3 (17). Additionally, in 2013 Arshi nazi et 
al. in a case control study measured vitamin D3 level 
in 30 patients with acute myeloblastic leukemia 
(AML) and 56 patients with ALL with the age mean 
of 24. They found the mean of vitamin D3 in AML 
patients was 17 ng/ml and in ALL patients was 10.52 
which these finding corroborate our results (18).  
In ALL steroid resistance and hypovitaminosis 
D are  reported  that both associated with a poor 
prognosis  Glucocorticoids (GC) are currently use as 
a treatment protocols in T-cell acute lymphoblastic 
leukemia and  its effect is mainly through the 
induction of apoptosis (19). Pistor, Met.al has 
demonstrated that 1,25-OH2 vitamin D3 upregulates 
the GC receptor and increases GC induced apoptosis 
(19). 
Other  investigation has reveals that three 
quarters of the patients have total vitamin D intake 
below the RDI (Recommended dietary intakes) 400 
IU/day (20) Vitamin  D,  through  its  hormonal  
metabolite  1a,25-dihydroxyvitamin D3, is also  a 
key factor influencing bone mass accretion  (20).  
The presented study should only be interpreted 
as a pilot investigation in which vitamin D3 
concentrations was determined in ALL patients. 
Furthermore, our study clearly argues for additional 
research, for example, to investigate the effect of 
vitamin D3 on the therapeutic efficacy of 
glucocorticoids and methotrexate in both B- and T- 
ALL patients and it might has clinical implications 
for therapeutic resistant ALL. 
Conclusion 
          There is possible association between initiation 
of acute leukemia and vitamin D3 deficiency. 
Accordingly, it is important to carry out some other 
investigations in different locations and more extended 
population to make it clearer and prescribe vitamin D3 
to deficient people to prevent acute leukemia. Vitamin 
D3 deficiency might also has a role in treatment of 
ALL. 
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